AR046510A1 - Composicion de un antagonista de vegf y un agente anti-proliferativo - Google Patents

Composicion de un antagonista de vegf y un agente anti-proliferativo

Info

Publication number
AR046510A1
AR046510A1 ARP040102585A ARP040102585A AR046510A1 AR 046510 A1 AR046510 A1 AR 046510A1 AR P040102585 A ARP040102585 A AR P040102585A AR P040102585 A ARP040102585 A AR P040102585A AR 046510 A1 AR046510 A1 AR 046510A1
Authority
AR
Argentina
Prior art keywords
vegf
proliferative agent
composition
agent
vegf antagonist
Prior art date
Application number
ARP040102585A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Publication of AR046510A1 publication Critical patent/AR046510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Una composición farmacéutica que comprende un antagonista del factor de crecimiento celular endotelial vascular (VEGF), tal como una trampa VEGF, una agente anti-proliferativo, tal como taxol, y un portador farmacéuticamente aceptable. Reivindicación 6: Un articulo de fabricación, que comprende: (a) material de envasado; y (b) un agente farmacéutico contenido dentro del material envasado, donde el agente farmacéutico comprende por lo menos una dosis de trampa de factor del crecimiento endotelial vascular (VEGF) y por lo menos un agente anti-proliferativo, y donde el material de envasado indica que el antagonista de VEGF y el agente anti-proliferativo pueden utilizarse para tratar el cáncer o reducir el crecimiento tumoral.
ARP040102585A 2003-07-25 2004-07-21 Composicion de un antagonista de vegf y un agente anti-proliferativo AR046510A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49000203P 2003-07-25 2003-07-25
US49397103P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
AR046510A1 true AR046510A1 (es) 2005-12-14

Family

ID=34118812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102585A AR046510A1 (es) 2003-07-25 2004-07-21 Composicion de un antagonista de vegf y un agente anti-proliferativo

Country Status (17)

Country Link
US (1) US7354579B2 (es)
EP (1) EP1648428A2 (es)
JP (1) JP5355856B2 (es)
KR (1) KR101175990B1 (es)
AR (1) AR046510A1 (es)
AU (1) AU2004261165C1 (es)
BR (1) BRPI0412798A (es)
CA (1) CA2529742C (es)
IL (1) IL172406A (es)
MX (1) MXPA05013642A (es)
MY (1) MY149169A (es)
NO (1) NO20060924L (es)
NZ (1) NZ544570A (es)
RU (1) RU2353353C2 (es)
TW (1) TWI351953B (es)
UY (1) UY28438A1 (es)
WO (1) WO2005011734A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399484B1 (en) * 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
CA2597247A1 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
ATE531365T1 (de) 2005-02-18 2011-11-15 Abraxis Bioscience Llc Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006104852A2 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
EP1957536A2 (en) * 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
WO2007139930A2 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
MX2008016124A (es) * 2006-06-16 2009-01-20 Regeneron Pharma Formulaciones antagonistas de vegf adecuadas para la administracion intravitreal.
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2125002A4 (en) * 2007-03-14 2011-02-23 Mayo Foundation TREATMENT OF SKIN CANCER
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
LT5610B (lt) 2007-12-17 2009-11-25 Uab Baltec Cnc Technologies, , Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas
SI2310011T1 (sl) * 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PL2552415T3 (pl) 2010-03-29 2017-03-31 Abraxis Bioscience, Llc Sposoby leczenia nowotworu
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
MY162903A (en) 2010-06-04 2017-07-31 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
CN113134095A (zh) 2014-06-16 2021-07-20 梅约医学教育与研究基金会 治疗骨髓瘤
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2732925T3 (es) 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
AU2016326510B2 (en) 2015-09-23 2022-03-10 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of Tie-2
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research HEMATOLOGICAL CANCER TREATMENTS
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
EP3506950A1 (en) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Methods and compositions for targeting t-cell cancers
JP2019526578A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリアー−ｐｄ−ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
EP3589324A1 (en) 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
AU2022275786A1 (en) 2021-05-17 2023-04-06 Bayer Healthcare Llc Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
US20240024420A1 (en) 2022-03-15 2024-01-25 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
WO2023177689A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
RS50073B (sr) * 1999-06-08 2009-01-22 Regeneron Pharmaceuticals I.N.C., Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression

Also Published As

Publication number Publication date
CA2529742C (en) 2012-09-18
US20050032699A1 (en) 2005-02-10
KR101175990B1 (ko) 2012-08-23
TW200524589A (en) 2005-08-01
NO20060924L (no) 2006-04-25
CA2529742A1 (en) 2005-02-10
US7354579B2 (en) 2008-04-08
MY149169A (en) 2013-07-31
AU2004261165B2 (en) 2009-07-16
AU2004261165C1 (en) 2009-12-17
WO2005011734A3 (en) 2005-04-14
WO2005011734A2 (en) 2005-02-10
EP1648428A2 (en) 2006-04-26
AU2004261165A1 (en) 2005-02-10
JP5355856B2 (ja) 2013-11-27
BRPI0412798A (pt) 2006-09-26
UY28438A1 (es) 2004-11-08
NZ544570A (en) 2008-08-29
IL172406A0 (en) 2006-04-10
JP2007500131A (ja) 2007-01-11
TWI351953B (en) 2011-11-11
IL172406A (en) 2016-04-21
RU2353353C2 (ru) 2009-04-27
KR20060028654A (ko) 2006-03-30
MXPA05013642A (es) 2006-03-10
RU2006105496A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
AR050418A1 (es) Dosificacion fija de anticuerpos her
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
CO6251236A2 (es) Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico
AR109263A2 (es) Composición que comprende moxidectina
NZ588913A (en) Liver cancer drug
ECSP034868A (es) Cápsulas para inhalación
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
AR091967A1 (es) Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
AR112103A1 (es) Compuestos para el tratamiento de tnbc
ES2530731T3 (es) Dispositivos médicos que contienen nitroprusiato y agentes antimicrobianos
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab

Legal Events

Date Code Title Description
FB Suspension of granting procedure